GoAI
Get started
Akanda Corp. logo

Akanda Corp.

AKAN

NASDAQHealthcareDrug Manufacturers - Specialty & Generic

Open in GoAI

Previous close

$3.86

−$0.04 · -1.03%

Aug 21, 4:00 PM ET

AKAN company overview

Regular session · ET · Market data may be delayed.

GoAI snapshot

AI-powered factor overview

Jul 10, 2026

GoAI score

Strong Sell

Exit — multiple negative signals converging

Valuation

2

Overpriced

Momentum

19

Strong Down

Sentiment

51

Mixed

Risk resilience

28

High Risk

Full GoAI research

Thesis, catalysts, evidence, and risk analysis.

View full GoAI research

AI-generated, informational only, and not investment advice.

Company profile

Company website

Akanda Corp., operating through its various subsidiary entities, focuses on the cultivation, production, and distribution of cannabis products. The company's operations span the United Kingdom, Lesotho, and other global regions, with a specific aim to provide cannabis-derived items for medical and wellness purposes. Formed in 2021, Akanda Corp. is based out of its main office in New Romney, United Kingdom.

Industry
Drug Manufacturers - Specialty & Generic
Sector
Healthcare
Headquarters
CA
CEO
Katharyn Field
Listed since
Mar 15, 2022
Employees
8

Market position

Day range

Current $3.86

52-week range

Current $3.86

Open
$3.96
Previous close
$3.90
Volume
164.81K
0.08× average
Average volume
2.05M
Average daily volume
Market cap
124.93K USD
Beta
1.73
Market reference 1
50-day average
$9.6966
-60.19% below average
200-day average
$12.4393
-68.97% below average

Financials

Financial snapshot

Latest / TTM

Valuation & yield

P/E (TTM)
-0.01×
P/B (TTM)
-0.02×
P/S (TTM)
0.48×
Dividend yield
0.00%

Profitability & efficiency

Gross margin
-382.68%
Operating margin
-2022.68%
Net margin
-17658.53%

Financial health

Debt / equity
-1.32×

Financial statements

Margin trends

Profitability as a percentage of reported revenue.

Gross marginOperating marginNet margin
Gross, operating, and net margin trends2100%-5800%-13701%-21601%Gross margin, FY2021: -1725.10%Gross margin, FY2022: 124.81%Gross margin, FY2023: 5.16%Gross margin, FY2024: 24.91%Gross margin, FY2025: -60.46%Operating margin, FY2021: -6203.45%Operating margin, FY2022: -770.18%Operating margin, FY2023: -465.33%Operating margin, FY2024: -523.80%Operating margin, FY2025: -1930.99%Net margin, FY2021: -19625.88%Net margin, FY2022: -445.00%Net margin, FY2023: -1494.18%Net margin, FY2024: -489.57%Net margin, FY2025: -17690.19%FY2021FY2022FY2023FY2024FY2025
Gross margin FY2021 -1725.10%. Gross margin FY2022 124.81%. Gross margin FY2023 5.16%. Gross margin FY2024 24.91%. Gross margin FY2025 -60.46%. Operating margin FY2021 -6203.45%. Operating margin FY2022 -770.18%. Operating margin FY2023 -465.33%. Operating margin FY2024 -523.80%. Operating margin FY2025 -1930.99%. Net margin FY2021 -19625.88%. Net margin FY2022 -445.00%. Net margin FY2023 -1494.18%. Net margin FY2024 -489.57%. Net margin FY2025 -17690.19%.

Income trends

Revenue

258.08K USD-69.15%

Operating income

−4.98M USD-13.71%

Net income

−45.65M USD-1014.59%
Income trends across reported periods7.45M USD−11.86M USD−31.17M USD−50.48M USDRevenue, FY2021: 41.43K USDRevenue, FY2022: 2.62M USDRevenue, FY2023: 2.16M USDRevenue, FY2024: 836.66K USDRevenue, FY2025: 258.08K USDOperating income, FY2021: −2.57M USDOperating income, FY2022: −20.18M USDOperating income, FY2023: −10.05M USDOperating income, FY2024: −4.38M USDOperating income, FY2025: −4.98M USDNet income, FY2021: −8.13M USDNet income, FY2022: −11.66M USDNet income, FY2023: −32.28M USDNet income, FY2024: −4.1M USDNet income, FY2025: −45.65M USDFY2021FY2022FY2023FY2024FY2025
Revenue FY2021 41.43K USD. Revenue FY2022 2.62M USD. Revenue FY2023 2.16M USD. Revenue FY2024 836.66K USD. Revenue FY2025 258.08K USD. Operating income FY2021 −2.57M USD. Operating income FY2022 −20.18M USD. Operating income FY2023 −10.05M USD. Operating income FY2024 −4.38M USD. Operating income FY2025 −4.98M USD. Net income FY2021 −8.13M USD. Net income FY2022 −11.66M USD. Net income FY2023 −32.28M USD. Net income FY2024 −4.1M USD. Net income FY2025 −45.65M USD.
Metric (USD)FY2025FY2024FY2023FY2022FY2021
Revenue258.08K USD836.66K USD2.16M USD2.62M USD41.43K USD
Cost of goods sold414.1K USD628.28K USD2.05M USD649.88K USD756.16K USD
Gross profit−156.02K USD208.38K USD111.45K USD3.27M USD−714.73K USD
Selling, general, and administrative4.39M USD4.45M USD5.88M USD19.85M USD5.81M USD
Operating expenses4.83M USD4.59M USD10.16M USD22.15M USD6.12M USD
Interest income—6.49K USD39 USD886 USD90 USD
Interest expense925.09K USD100.11K USD255.66K USD115.32K USD10.51K USD
Depreciation and amortization433.69K USD141.05K USD4.28M USD3.6M USD309.02K USD
Operating income−4.98M USD−4.38M USD−10.05M USD−20.18M USD−2.57M USD
Net income−45.65M USD−4.1M USD−32.28M USD−11.66M USD−8.13M USD

Company facts updated Aug 24, 2026.

Earnings

Latest EPS result
-41.24

EPS: actual versus estimate

Recent quarterly results

ActualEstimate
Estimates unavailable
Quarterly EPS actual values compared with estimates6.06-22.22-50.51-78.79Q4 '20Q3 '21Q4 '21Q3 '23Q3 '24Q3 '25
Q4 2020, reported Dec 31, 2020: actual 0.207, estimate —, surprise —, Comparison unavailable. Q3 2021, reported Sep 30, 2021: actual -1.67, estimate —, surprise —, Comparison unavailable. Q4 2021, reported Dec 31, 2021: actual -0.973, estimate —, surprise —, Comparison unavailable. Q3 2023, reported Aug 7, 2023: actual -72.94, estimate —, surprise —, Comparison unavailable. Q3 2024, reported Aug 7, 2024: actual -3.55, estimate —, surprise —, Comparison unavailable. Q3 2025, reported Jul 30, 2025: actual -41.24, estimate —, surprise —, Comparison unavailable.

Revenue: actual versus estimate

Recent quarterly results

ActualEstimate
Estimates unavailable
Quarterly Revenue actual values compared with estimates1.51M1.01M503.23K232.9Q4 '20Q3 '21Q4 '21Q3 '23Q3 '24
Q4 2020, reported Dec 31, 2020: actual 274 USD, estimate —, surprise —, Comparison unavailable. Q3 2021, reported Sep 30, 2021: actual 13.42K USD, estimate —, surprise —, Comparison unavailable. Q4 2021, reported Dec 31, 2021: actual 24.07K USD, estimate —, surprise —, Comparison unavailable. Q3 2023, reported Aug 7, 2023: actual 1.4M USD, estimate —, surprise —, Comparison unavailable. Q3 2024, reported Aug 7, 2024: actual 477.01K USD, estimate —, surprise —, Comparison unavailable.

AKAN news

benzinga.com

Akanda Stock Surges Friday: What's Driving the Action?

Akanda Corp. (NASDAQ:AKAN) shares are climbing Friday morning after its wholly owned subsidiary, First Towers & Fiber Corp. (FTF), delivered a comprehensive operational and expansion update.

Read source
newsfilecorp.com

Akanda's First Towers & Fiber Increases Recurring Revenue with Completion of 200 KM Fiber Network

Toronto, Ontario--(Newsfile Corp. - August 13, 2026) - Akanda Corp. (NASDAQ: AKAN) ("Akanda") and its 100% owned subsidiary First Towers & Fiber Corp. ("FTF" or the "Company"), an emerging telecommunications…

Read source
newsfilecorp.com

Coloured Ties Capital Announces Proposed Share Consolidation

Vancouver, British Columbia--(Newsfile Corp. - July 6, 2026) - Coloured Ties Capital Inc. (TSXV: TIE) (OTC Pink: APEOF) (FSE: 97A0) ("Coloured Ties" or the "Company") announces that the Company intends to consolidate the…

Read source
newsfilecorp.com

Akanda Announces Receipt of Nasdaq Notice Regarding Minimum Stockholders' Equity Requirement

Toronto, Ontario--(Newsfile Corp. - June 18, 2026) - Akanda Corp. (NASDAQ: AKAN) (the "Company" or "Akanda"), today announced that it received a notification letter from the Listing Qualifications Department of The…

Read source
newsfilecorp.com

Akanda Corp. Regains Compliance with Nasdaq Periodic Filing Requirement

Filing of Annual Report on Form 20-F for Fiscal 2025 Restores Compliance with Nasdaq Listing Rule 5250(c)(1) Toronto, Ontario--(Newsfile Corp. - June 12, 2026) - Akanda Corp. (NASDAQ: AKAN) (the "Company" or "Akanda"),…

Read source

AKAN peers

Amgen Inc. logo

AMGN

Amgen Inc.

$439.33

+1.29%

Gilead Sciences, Inc. logo

GILD

Gilead Sciences, Inc.

$146.12

+1.87%

Vertex Pharmaceuticals Incorporated logo

VRTX

Vertex Pharmaceuticals Incorporated

$548.05

+1.44%

Intuitive Surgical, Inc. logo

ISRG

Intuitive Surgical, Inc.

$378.81

+1.16%

Sanofi logo

SNY

Sanofi

$45.85

+1.55%

Regeneron Pharmaceuticals, Inc. logo

REGN

Regeneron Pharmaceuticals, Inc.

$834.04

+0.90%

Continue in GoAI

Research AKAN

research.disclaimer